Rafael

Yahoo Finance • 5 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) f... Full story

Yahoo Finance • 5 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Bo... Full story

Yahoo Finance • 7 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating... Full story

Yahoo Finance • 9 months ago

Rafael Holdings elects Scott Fine as ex-officio director and amends bylaws

Rafael Holdings, Inc. (NYSE:RFL), a small-cap company with a market capitalization of $80 million, reported Monday the election of N. Scott Fine as an ex-officio (non-voting) director and vice chairman of the company. According to Investin... Full story

Yahoo Finance • 10 months ago

Thursday Sector Leaders: Precious Metals, Real Estate Stocks

In trading on Thursday, precious metals shares were relative leaders, up on the day by about 1.1%. Leading the group were shares of Western Copper & Gold, up about 7.4% and shares of Avino Silver & Gold Mines up about 6.2% on the day. Al... Full story

Yahoo Finance • 10 months ago

Rafael Holdings GAAP EPS of -$0.19, revenue of $0.36M

* Rafael Holdings press release [https://seekingalpha.com/pr/20132985-rafael-holdings-reports-third-quarter-fiscal-2025-financial-results] (NYSE:RFL [https://seekingalpha.com/symbol/RFL]): Q3 GAAP EPS of -$0.19. * Revenue of $0.36M (+5... Full story

Yahoo Finance • 10 months ago

Tuesday 6/10 Insider Buying Report: POST, RFL

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Thursday, Post Holdings' Director, Willi... Full story

Yahoo Finance • last year

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareho... Full story

Yahoo Finance • last year

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025... Full story

Yahoo Finance • 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April... Full story

Yahoo Finance • 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

NEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committe... Full story

Yahoo Finance • 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet al... Full story

Yahoo Finance • 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully complete... Full story

Yahoo Finance • 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spen... Full story

Yahoo Finance • 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results for the three and twelve month... Full story

Yahoo Finance • 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022

CRANBURY, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that data o... Full story

Yahoo Finance • 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publicati... Full story

Yahoo Finance • 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and nine months ended April 30,... Full story

Yahoo Finance • 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Comp... Full story